Skip to main content
. 2021 Aug 10;14(11):101197. doi: 10.1016/j.tranon.2021.101197

Fig. 3.

Fig. 3

RES scores accurately predict response and survival of melanoma patients to immunotherapy. (A) Logistic regression models from Pembrolizumab-treated patients for 13 upregulated RES score means and responding prediction for responder (R, blue) and non-responder (NR, red) patients. (B) Logistic regression models from Pembrolizumab-treated patients for 248 downregulated RES score means and responding prediction for responder (R, blue) and nonresponder (NR, red) patients. (C) Logistic regression models from Nivolumab-treated patients for 29 upregulated RES score means and responding prediction for responder (R, blue) and non-responder (NR, red) patients. (D) Logistic regression models from Nivolumab-treated patients for 41 downregulated RES score means and responding prediction for responder (R, blue) and non-responder (NR, red) patients. (E) Survival analysis of patients stratified by upper 50% (red) and lower 50% (blue) means of upregulated RES scores for genes in the Pembrolizumab cohort. (F) Survival analysis of patients stratified by upper 50% (red) and lower 50% (blue) means of upregulated RES scores for genes in the Nivolumab cohort. (G) Survival analysis of patients stratified by upper 50% (purple) and lower 50% (green) means of downregulated RES scores for genes in the Pembrolizumab cohort. (H) Survival analysis of patients stratified by upper 50% (purple) and lower 50% (green) means of downregulated RES scores for genes in the Nivolumab cohort (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).